158 related articles for article (PubMed ID: 25261371)
1. Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma.
Goldshmit Y; Trangle SS; Kloog Y; Pinkas-Kramarski R
Oncotarget; 2014 Sep; 5(18):8602-13. PubMed ID: 25261371
[TBL] [Abstract][Full Text] [Related]
2. Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death.
Schokoroy S; Juster D; Kloog Y; Pinkas-Kramarski R
PLoS One; 2013; 8(9):e75269. PubMed ID: 24086490
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras.
Farin K; Schokoroy S; Haklai R; Cohen-Or I; Elad-Sfadia G; Reyes-Reyes ME; Bates PJ; Cox AD; Kloog Y; Pinkas-Kramarski R
Cancer Res; 2011 Mar; 71(6):2140-51. PubMed ID: 21257709
[TBL] [Abstract][Full Text] [Related]
4. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.
Wolfson E; Solomon S; Schmukler E; Goldshmit Y; Pinkas-Kramarski R
Cell Death Dis; 2018 Jan; 9(2):47. PubMed ID: 29352243
[TBL] [Abstract][Full Text] [Related]
5. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Benedetti E; Antonosante A; d'Angelo M; Cristiano L; Galzio R; Destouches D; Florio TM; Dhez AC; Astarita C; Cinque B; Fidoamore A; Rosati F; Cifone MG; Ippoliti R; Giordano A; Courty J; Cimini A
Oncotarget; 2015 Dec; 6(39):42091-104. PubMed ID: 26540346
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel antagonist of the ErbB1 receptor capable of inhibiting migration of human glioblastoma cells.
Staberg M; Riemer C; Xu R; Dmytriyeva O; Bock E; Berezin V
Cell Oncol (Dordr); 2013 Jun; 36(3):201-11. PubMed ID: 23580313
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.
Lang L; Shay C; Zhao X; Teng Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):112. PubMed ID: 28830537
[TBL] [Abstract][Full Text] [Related]
8. Structure-function analysis of nucleolin and ErbB receptors interactions.
Farin K; Di Segni A; Mor A; Pinkas-Kramarski R
PLoS One; 2009 Jul; 4(7):e6128. PubMed ID: 19578540
[TBL] [Abstract][Full Text] [Related]
9. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.
Krust B; El Khoury D; Nondier I; Soundaramourty C; Hovanessian AG
BMC Cancer; 2011 Aug; 11():333. PubMed ID: 21812966
[TBL] [Abstract][Full Text] [Related]
10. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
[TBL] [Abstract][Full Text] [Related]
11. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
[TBL] [Abstract][Full Text] [Related]
12. Growth Factor Midkine Aggravates Pulmonary Arterial Hypertension via Surface Nucleolin.
Kinoshita D; Shishido T; Takahashi T; Yokoyama M; Sugai T; Watanabe K; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Miyamoto T; Watanabe T; Kishida S; Kadomatsu K; Abe JI; Takeishi Y; Konta T; Kubota I; Watanabe M
Sci Rep; 2020 Jun; 10(1):10345. PubMed ID: 32587339
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
16. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
17. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
18. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
Blum R; Jacob-Hirsch J; Rechavi G; Kloog Y
Mol Cancer Ther; 2006 Sep; 5(9):2337-47. PubMed ID: 16985068
[TBL] [Abstract][Full Text] [Related]
19. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.
Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R
Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246
[TBL] [Abstract][Full Text] [Related]
20. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines.
Gallo-Oller G; Vollmann-Zwerenz A; Meléndez B; Rey JA; Hau P; Dotor J; Castresana JS
Cancer Lett; 2016 Oct; 381(1):67-75. PubMed ID: 27473823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
